HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan

HBI-8000 granted orphan drug designation for peripheral T-cell lymphoma in Japan

San Diego, CA, USA – December 22, 2015HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

Read more

HUYA Bioscience International Sponsors ‘Best New Drug’ Category at SCRIP Awards

Supports Prestigious Award Recognizing Excellence in Pharmaceutical Development

San Diego, CA, USA – December 3, 2015HUYA Bioscience International (HUYA) was a proud sponsor of the ‘Best New Drug’ category at the 11th Annual SCRIP Awards. Dr. Mireille Gillings was a finalist for ‘Executive of the Year’ and HUYA was a finalist for ‘Best Company in an Emerging Market’. These prestigious awards recognize excellence in the biopharmaceutical industry. HUYA CEO and Executive Chairman, Dr. Mireille Gillings, presented HUYA Bioscience’s Best New Drug Award to Novartis which was recognized for the launch of its new product Cosentyx (secukinumab), a therapy for psoriasis. The award was presented at a ceremony at the Grosvenor House Hotel in London, attended by over 300 industry leaders.

Read more

HUYA Bioscience International Expands into South Korea

Seoul Office Will Head Operations to Develop Korean Biopharmaceutical Innovation

Seoul, Korea – December 2, 2015HUYA Bioscience International (HUYA), the global leader in accelerating drug discovery and development of biopharma innovation originating in China, recently opened its first Corporate office in Korea. This continues to build on HUYA’s overall strategy to be the partner-of-choice for innovative pharmaceutical companies in emerging centers of excellence worldwide.

Read more

HUYA Bioscience International Announces a Strategic Alliance with the Korea Drug Development Fund

San Diego, CA, USA – November 30, 2015 –HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed a Memorandum of Understanding with the Korea Drug Development Fund (KDDF) to foster collaboration between KDDF and HUYA with the ultimate goal of advancing Korean development and commercialization of healthcare products for the global market.

Read more

HUYA Bioscience International Celebrates its 10th Anniversary

San Diego Biotech Firm Commemorates a Decade of Innovation

San Diego, CA, USA – November 16, 2015 –HUYA Bioscience International (HUYA) just celebrated its 10th anniversary of the company’s founding with a black tie gala event on November 13 at the U.S. Grant Hotel in San Diego. The company honored its 10 years of international pharmaceutical innovation and development with live entertainment and video greetings from colleagues and key opinion leaders in Japan and China.

Read more

HUYA Bioscience International and TechCode Gu’an Lifesciences Park Establish Strategic Collaboration

San Diego, CA, USA – November 9, 2015 –HUYA Bioscience International, the leader in accelerating the global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with TechCode Gu’an Life Sciences Park (referred to as TechCode Gu’an Park). The collaboration will focus on promoting the development of biomedical innovations from companies located in the park that could help meet the growing demand to fill global pharmaceutical pipelines.

Read more

HUYA Bioscience International Further Expands Executive Team

Appoints Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer

San Diego, CA, USA – September 15, 2015 –HUYA Bioscience International (HUYA) today announced the expansion of its Executive Team with the appointment of Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer.

Read more

HUYA Bioscience International Announces Epigenetic Breast Cancer Program

Expansion marked by clinical development for multiple HER2 subtypes of breast cancer

San Diego, CA, USA – September 3, 2015 –HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

Read more

HUYA Bioscience International Sponsors Japan Society of HTLV-1 Annual Meeting

San Diego, CA, USA – August 27, 2015 –HUYA Bioscience International (HUYA) today announced the sponsorship of the second annual meeting of the Japan Society of HTLV-1, held this week at the University of Tokyo Medical Science Institute Auditorium.

Read more

HUYA Bioscience International CEO, Mireille Gillings, Ph.D., Named As Gold Award Winner In 2015 American Business Awards

13th annual Stevie® Awards presented on June 22 in Chicago

San Diego, CA, USA – June 23, 2015 –HUYA Bioscience International CEO and Executive Chairman, Mireille Gillings, Ph.D., has been named a Gold Stevie® Award Winner in the ‘Woman of the Year, Health Products and Services & Pharmaceuticals’ category in The 2015 American Business Awards.

Read more